Shanghai EPN and BioMap Reached a Strategic Cooperation

News

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2021-05-11

Source: Viva Biotech

[Abstract]:To jointly work on the development of autoimmune diseases therapies

Shanghai, China-Recently, Shanghai EPN, a biotech start-up company invested and incubated by Viva BioInnovator, have reached a strategic cooperation agreement with BioMap to focus on autoimmune diseases cooperative development of multi-omics joint analysis of specific clinical problems and functional omics disease maps of specific diseases.

Previous Page：TechnoDerma Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S. Next Page：Anji Pharmaceutical Accelerates Phase II Clinical Study of ANJ908

Back

Media contact: vivapr@vivabiotech.com